Engineered HSV-1 Vectors for High-Capacity Genetic Circuit Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Viral vectors, such as those based on Herpes Simplex Virus-1 (HSV-1), face challenges including toxicity, interference with transgene expression, and limitations in the size of transgenes that can be delivered.
Innovation Solution
Engineered HSV-1 vectors with a modified genome, featuring deletions in genes like ICP4, ICP0, VP16, and others, are developed to attenuate the virus, reducing toxicity while allowing for high-titer viral particle production and robust transgene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral vectors are used to deliver transgenes, then transgene delivery is achieved, but toxicity is induced and transgene expression is interfered with
Solution Approach 1:
The patent extracts and removes specific viral genes (ICP4, ICP0, VP16, γ34.5, LAT, ICP6, ICP8, ICP27, ICP22, and ICP47) from the HSV-1 genome to create an attenuated vector. This extraction eliminates the harmful toxic effects and immune interference caused by these genes while preserving the vector's ability to deliver transgenes effectively.
Solution Approach 2:
The patent changes the genetic parameters of the HSV-1 vector by introducing specific deletions in virulence-associated genes. This parameter change transforms the virus from a highly virulent form that causes toxicity into an attenuated form that is safe for therapeutic use while maintaining transgene delivery capability.
2Object-affected harmful factors
If viral vectors are attenuated to reduce toxicity, then safety is improved, but transgene expression and viral particle production are reduced
Solution Approach 1:
The patent introduces packaging cell lines that serve as intermediaries to compensate for the deleted viral genes. These packaging cells provide the necessary viral proteins in trans, allowing the attenuated vector to produce high-titer viral particles and achieve robust transgene expression without requiring the deleted virulence genes.
3Object-affected harmful factors
If viral vectors are attenuated to reduce immune response, then safety is improved, but viral particle titer is reduced
Solution Approach 1:
The patent uses packaging cell lines as intermediaries to produce high-titer viral particles containing the attenuated vector. The packaging cells compensate for the immune-evasion gene deletions by providing the necessary viral proteins, enabling high-level viral particle production that elicits reduced immune response while maintaining sufficient titer for effective delivery.
Data Source
AI summary
Provided herein are engineered HSV-1 vectors comprising a modified HSV-1 genome. The engineered HSV-1 vectors can be used to deliver genetic circuits (e.g., up to 100 kb) to cells in vitro or in vivo. Methods of treating or diagnosing a disease (e.g., cancer) using the engineered HSV-1 vectors described herein are also provided.